Status:

TERMINATED

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Lead Sponsor:

CRISPR Therapeutics AG

Conditions:

T Cell Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.

Detailed Description

The study may enroll approximately 45 subjects in total.

Eligibility Criteria

Inclusion

  • Inclusion Criteria (abbreviated):
  • Age ≥18 years.
  • Confirmed diagnosis of a T cell malignancy or Diffuse Large B-Cell Lymphoma (DLBCL).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Adequate renal, liver, cardiac, and pulmonary organ function.
  • Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX130 infusion.
  • Exclusion Criteria (abbreviated):
  • Prior allogeneic stem cell transplant (SCT).
  • Prior treatment with any anti-CD70 targeting agents.
  • History of certain central nervous system (CNS), cardiac or pulmonary conditions.
  • Active HIV, hepatitis B virus or hepatitis C virus infection.
  • Previous or concurrent malignancy, except treated with curative approach not requiring systemic therapy and in remission for \>12 months, or any other localized malignancy with low risk of developing into metastatic disease.
  • Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
  • Prior solid organ transplantation.
  • Pregnant or breastfeeding females.

Exclusion

    Key Trial Info

    Start Date :

    July 31 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 30 2024

    Estimated Enrollment :

    49 Patients enrolled

    Trial Details

    Trial ID

    NCT04502446

    Start Date

    July 31 2020

    End Date

    August 30 2024

    Last Update

    January 8 2025

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Research Site 2

    Duarte, California, United States, 91010

    2

    Research Site 5

    Stanford, California, United States, 94305

    3

    Research Site 10

    New Haven, Connecticut, United States, 06520

    4

    Research Site 4

    Miami, Florida, United States, 33124

    A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | DecenTrialz